Home
Contact
Careers
Terms and Conditions
Privacy Policy
About Arcturus
RNA Medicines
Technologies
Pipeline
Business Development
Publications
Investor Relations

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

August 18, 2022

Home
Contact
Careers
Terms and Conditions
Privacy Policy
© 2023 Arcturus Therapeutics, Inc.